Mounjaro / Zepbound (Tirzepatide): An honest audit
Weekly dual GLP-1/GIP receptor agonist injection
6/10
Sustainability
10/10
Short term
7/10
Long term
Three numbers, one rubric
Category
Pharma
Typical cost
~$1100/mo
First visible change
~28 days
Evidence rating
Strong evidence
Studies cited
4
How to read these scores
Sustainability
Weighted heaviest. Adherence predicts outcome more reliably than macro split, so an approach nobody can keep scores low here even when the trial data looks good.
Short-term effect
A high number here alone means very little. Water and glycogen move fast, and almost every restrictive protocol looks impressive at week four.
Long-term effect
Where short-term and long-term diverge sharply, you are usually looking at a regain mechanism built into the design — not a willpower failure.
What it promises — and how it says it works
The claim
What it claims
Tirzepatide (Mounjaro for T2D, Zepbound for weight management) is a once-weekly dual GLP-1/GIP receptor agonist. SURMOUNT-1 trial reported 20.9% mean weight loss at 72 weeks at the highest dose — the largest non-surgical effect in trial history.
The mechanism
How it is supposed to work
Adds GIP (glucose-dependent insulinotropic polypeptide) agonism to the GLP-1 mechanism. The dual incretin pathway produces stronger appetite suppression and gastric-emptying delay than GLP-1 alone. Same metabolic mechanism (calorie reduction), pharmacologically more powerful.
What the research actually shows
SURMOUNT-1¹ produced 20.9% weight loss at 72 weeks (vs 3.1% placebo). SURMOUNT-2 in T2D produced 15.7%. Body-composition substudies show similar lean-mass-loss patterns as semaglutide. No mature SELECT-equivalent CV outcomes trial yet, but cardiometabolic improvements consistent with semaglutide. Discontinuation regain pattern likely similar.¹²³⁴
Footnote numbers link to the full reference list at the foot of this page.
Evidence rating
Strong evidence
Describes the quality and quantity of the peer-reviewed literature — trial count, duration, sample size and replication — not our opinion of the approach.
Early loss is not evidence. Glycogen carries roughly three grams of water per gram, so the first pounds on almost any restrictive protocol are largely water. What matters is what is still there at twelve and twenty-four months.
Right person, wrong person
Almost nothing on this site is universally good or universally useless. The useful question is which body, kitchen and calendar an approach was built for.
Worth a trial
Who it works for
Same population as semaglutide — BMI ≥30 with comorbidity, willing to commit to long-term treatment plus serious lifestyle protocol. Stronger effect; consider when semaglutide produces inadequate response.
Look elsewhere
Who it fails
Same as semaglutide — adults with cosmetic-grade weight loss goals and no serious comorbidity. Adults unwilling or unable to maintain protein adequacy and resistance training. Pricing/access constraints.
Tirzepatide is the most powerful non-surgical weight-loss drug in history. The clinical-use calculus is otherwise the same as semaglutide: appropriate for BMI ≥30 with comorbidity, requires long-term commitment plus active countermeasures against muscle and bone loss. The longer-term safety data is younger than semaglutide's.
Written against the rubric, not against a sponsor. Individual response varies and no outcome is guaranteed.
What to do instead
Same as semaglutide audit. If you don't qualify for GLP-1 use, lifestyle-first.
Not sure which fits
Get a read on your profile
Fifteen questions, roughly two minutes, no email wall on the result. Returns a starter protocol matched to your metabolic situation.
Take the assessmentStraight answers
Mounjaro / Zepbound (Tirzepatide), without the spin
We score Mounjaro / Zepbound (Tirzepatide) 6/10 for sustainability, 10/10 for short-term effect and 7/10 for long-term effect. A gap between the short-term and long-term numbers is the single most common pattern in this index — an approach can move the scale quickly and still leave almost nothing behind eighteen months later.
Sustainability is weighted heaviest for a reason: across head-to-head trials, adherence predicts outcome more reliably than which named diet you picked. A protocol you abandon in week six did nothing at all.
Can you still be doing this in month twelve?
First 12 weeks in controlled trials
What survives at 12–24 months
Educational summaries of published research. Individual response varies and no outcome is guaranteed.
References
- 01Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. PubMed 35658024
- 02Linge J et al. (2024). Body composition and cardiometabolic effects of GLP-1 receptor agonists: changes in lean mass. Obesity Reviews. PubMed 38605467
- 03Jensen SBK et al. (2024). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Network Open. PubMed 38904957
- 04Lincoff AM et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. PubMed 37952131
Did Mounjaro / Zepbound (Tirzepatide) not work for you?
That is the rule rather than the exception, and it is usually a design problem in the protocol rather than a character problem in you. The assessment reads your situation and points you at the approach the research supports for that profile.
- Free, with no email wall on the result
- Fifteen questions, roughly two minutes
- Returns a starter protocol matched to your profile
- Every recommendation links back to its research
Educational only, not medical advice. This audit summarises published research and is not a diagnosis, a prescription, or a treatment plan. Consult your physician before major dietary changes or altering prescribed medication. These statements have not been evaluated by the Food and Drug Administration. Individual results vary; no outcome is guaranteed.